Terumo (4543) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
16 Jan, 2026Executive summary
Achieved record-high revenue and profits for the first half, with net sales up 15% year-over-year to ¥508.7 billion, driven by strong global demand and favorable foreign exchange rates.
Profit growth outpaced sales growth, supported by cost control, pricing measures, and favorable FX.
All major business segments and regions posted double-digit growth, with especially strong performance in the US and Europe.
Free cash flow reached a record high, aided by profit increase, working capital management, and reduced capital investment.
Upward revision of full-year forecast, expecting record sales and profits.
Financial highlights
Revenue for FY24 Q2 YTD rose 15% year-over-year to ¥508.7 billion; gross profit up 21% to ¥277.0 billion.
Operating profit increased 32% to ¥87.7 billion; adjusted operating profit up 38% to ¥104.0 billion.
Profit for the year up 26% to ¥63.2 billion; free cash flow surged 255% to ¥62.1 billion.
Gross margin improved to 54.5% from 51.4% year-over-year.
Cash and cash equivalents at period-end were ¥194.9 billion.
Outlook and guidance
Full-year adjusted operating income forecast revised upward from ¥185 billion to ¥200 billion, reflecting strong first-half performance and favorable FX.
FY2025 revenue forecast is ¥1,010.0 billion (+9.6% YoY), adjusted operating profit ¥200.0 billion (+27.6%), and EPS ¥84.10.
Dividend guidance for FY2025 is ¥26.00 per share, reflecting a two-for-one share split.
ROIC and ROE expected to improve to 7.9% and 9.2%, respectively.
Continued monitoring of macroeconomic risks, including raw material and transportation costs.
Latest events from Terumo
- Record revenue and profit growth, driven by global demand and strategic acquisitions.4543
Q3 202613 Feb 2026 - Record revenue and profit growth, with double-digit gains and improved margins.4543
Q1 20252 Feb 2026 - Innovation, M&A, and new launches fuel global growth and margin expansion.4543
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Record revenue and profit growth driven by global demand, pricing, and FX gains.4543
Q3 20258 Jan 2026 - $1.5B acquisition accelerates entry into organ transplantation, driving growth and innovation.4543
M&A Announcement23 Nov 2025 - Record revenue and profit, global expansion, and strategic investments; tariff risks persist.4543
Q4 202517 Nov 2025 - Record revenue and profit growth, upward guidance, but lower OP due to acquisition costs.4543
Q2 202614 Nov 2025 - Record profit and revenue growth, led by US, China, and plasma innovation segments.4543
Q1 20267 Aug 2025